Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer ... universal donor cell and gene editing technology it obtained ...
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...
Astellas has said it will book a $170 million ... both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753. The full financial impact of the delay to ...
Dealbreaker on MSN2mon
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & MoreCancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key ...
In light of this, Astellas, a global pharmaceutical company based in Tokyo, Japan, has set a long-term goal of advancing cell and gene therapies for treating eye diseases. Degenerative eye ...
6d
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
NEW YORK — To gene therapy pioneer Jim Wilson, the field is currently clouded with “irrational pessimism.” Companies are abandoning ship; approved therapies aren’t being prescribed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback